ECTRIMS 2022 | Validation of the MSDA test in plasma

A multivariate proteomic multiple sclerosis disease activity (MSDA) test, which measures the concentration of 18 proteins to determine four disease pathways and an overall disease activity score, has been analytically and clinically validated in serum. Ferhan Qureshi, BS, Vice President, Octave Bioscience, Menlo Park, CA, describes a study that validated the MSDA test in plasma. Matched serum and plasma samples were assayed, and it was found that the vast majority of proteins correlated well between plasma and serum. Although the correlation was strong, in some cases, there was an offset in the concentration. Using an adjustment factor to the concentration value in plasma provided a highly equivalent score to a serum sample. This interview took place at the ECTRIMS Congress 2022 in Amsterdam, The Netherlands.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.